

The background of the slide is a blurred laboratory setting. In the foreground, there are several small glass vials with silver caps and labels, some containing blue liquid. Behind them, there are larger test tubes, some containing red liquid, and a syringe. The overall color palette is dominated by blue and teal tones.

gerresheimer

Q1 2021 Results Presentation

Dietmar Siemssen, CEO

Bernd Metzner, CFO

Duesseldorf, April 8, 2021

Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Achieving our Targets as One Gerresheimer

CEO Dietmar Siemssen




gerresheimer

Accelerating Growth Momentum

Key Take-Aways Q1 2021


- **Q1 2021 good start to accelerate growth:**
 - Organic revenue growth in-line with guidance: +3.1% core¹ / +3.7% on group level
 - Adj. EBITDA margin core business: 19.0% (+80 basis points yoy)
 - Adj. EPS (FXN) surged +29.3% yoy
- **Steep increase in high value solutions:**
+40% yoy with Biologics growing +50% yoy
- **Accelerate growth in the second quarter – guidance confirmed**

1. The core business consists of the Plastics & Devices and the Primary Packaging Glass divisions; for adjusted EBITDA purposes also including head office/consolidation.



One Gerresheimer

One Company With Great Capabilities and Opportunities



- **Living One Gerresheimer:** we pulled down historical silos and formed a global team committed to our ambitious goals
- Consequent implementation of **formula G.** We transform into a growth company as innovation leader and solution provider
- Focus on customer centricity, excellence, cost efficiency, innovation and sustainability
- **Gx Biological Solutions continuously speeding-up**
- **Global network of innovation centers:** bundle knowhow and secure access for the whole company
- Build the future: accelerate on **smart, intelligent innovations**

Success Story Biological Solutions

Gx Biological Solutions a Good Showcase for One Gerresheimer

High Value Solutions are key growth driver –
for FY 2021 and going forward


Gx Biological Solutions:

Serving biotech customers with the whole Gerresheimer portfolio – as the go-to partner

- cross-divisional team
- Full-service provider for small, mid and large biotech companies


Main contributors for growth:

- Gx[®] RTF vials
- Gx[®] Elite Glass and ELITE RTF vials
- Gx RTF[®] syringes



Global Network is key for Innovation

Connecting Competencies Worldwide



- Promote innovations more strongly
- Innovation process defined
- Network of Innovation & Technical Competence Center
- Innovation Challenge
- Projects with partners
- Local expertise

Set for Strong Q2 – Financial Update

CFO Dr. Bernd Metzner


A large, bold, white number '2' is positioned in the lower right quadrant of the slide. It is a simple, sans-serif font.

gerresheimer

Q1 2021: Good Start Into the Year

Operational View of key KPIs

- **Q1 2021 organic revenue growth in core business of 3.1%**
- Both divisions P&D and PPG showing good organic growth rates with **significant revenue contribution from High Value Solutions**
- Headwinds in Moulded Glass cosmetics business in the amount of EUR 4m
- **Adj. EBITDA margin core business amounted to 19.0%** - and increase of 80 bps despite furnace replacement in PPG




Outstanding Performance of all Divisions

Q1 2021: Divisional Performance and Highlights

Organic growth yoy

In EUR m



Reconciliation Q1 2021

Reported and Adjusted Financials

In EUR m	Q1 2021			Q1 2020	YoY (FXN)
	Reported	Adjustment	Adjusted	Adjusted	Adjusted
Revenues	302.8		302.8	303.9	+3.7%
EBITDA	52.1	2.1	54.2	51.1	+9.6%
Depreciation & Amortization	-32.9	9.1	-23.9	-27.3	
EBIT	19.2	11.1	30.3	23.8	
Financial Result	-4.7	0.0	-4.7	-4.9	
EBT	14.5	11.1	25.6	18.9	
Income Taxes	-4.8	-2.3	-7.1	-5.4	
Non-controlling interests			-0.5	-0.1	
Adj. Net Income			18.0	13.5	+29.3%
Adj. EPS			0.57	0.43	+29.3%

Free Cash Flow and Net Debt Improvement

Cash Flow and Financial Debt Performance

In EUR m	Q1 2021	Q1 2020	Change
Adjusted EBITDA	54.2	51.1	+3.1
Change in net working capital	-45.6	-81.7	+36.1
Net interest paid	-1.9	-1.7	-0.2
Net taxes paid	-8.9	-7.7	-1.2
Other	-21.6	-5.1	-16.5
Cash flow from operating activities	-23.8	-45.1	+21.3
Net capex	-35.6	-32.8	-2.8
Free cash flow before M&A	-59.4	-77.9	+18.5
Net Financial Debt ¹	986	1,017	-31
Adj. EBITDA Leverage	3.2x	3.4x	-0.2x

1. Net financial debt according to credit agreement in force

2021 Outlook


CEO Dietmar Siemssen



gerresheimer

Set Ambitious Targets and Achieve Them


Growth Acceleration in the Mid-Term



The transformation is ongoing

Acceleration of Growth in Q2

Q2 2021 Projection and Outlook



Profitable Growth Accelerating

Guidance for FY 2021 and Mid-Term

For Core
Business¹
(FXN)


	FY 2021	Mid-term
Accelerate Revenue growth	Mid-single digit growth	High-single digit growth
Further expand Adj. EBITDA margin	~ 22 to 23%	~ 23%
Drive Adj. EPS growth and shareholder value	≥ 10% p.a.	

1. The core business consists of the Plastics & Devices and the Primary Packaging Glass divisions; for adj. EBITDA and adj. EPS purposes also including head office/consolidation.

Appendix



Financial Calendar



FINANCIAL CALENDAR

June 9, 2021

Annual General Meeting 2021

July 13, 2021

Interim Report 2nd Quarter Results 2021


October 12, 2021

Publication 3rd Quarter Results 2021




YoY Revenue & Organic Growth Reconciliation

(1 of 2) in EUR m



YoY EBITDA & Organic Growth Reconciliation

(2 of 2) in EUR m



Improving Financial Headroom

Net Financial Debt & Adjusted EBITDA Leverage


Net financial debt according to credit agreement in force



In EUR m	Q1 2020	Q1 2021
Drawn portion of the RCF	370	212
Promissory Note (2019)		325
Promissory Note (2017)	250	250
Promissory Note (2015)	425	236
Local borrowings	43	43
Installment Purchase Liabilities	1	1
Cash + cash equivalents	-72	-81
Net financial debt¹	1,017	986

Maturity Profile

In EUR m



1. Excluding lease liabilities.

gerresheimer

innovating for a better life